Advances in antiviral therapy

Dermatologic Clinics

Volumn 23, Issue 2, 2005, Pages 313-322

  Wu, Jashin J ^a   Pang, Katie R ^b   Huang, David B ^c,d,e   Tyring, Stephen K ^f,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g Center for Clinical Studies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BLEOMYCIN; CANTHARIDIN; CIDOFOVIR; CORTICOSTEROID; DNA VACCINE; ENZYME INHIBITOR; FAMCICLOVIR; FLUOROURACIL; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; HERPES SIMPLEX VACCINE; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; INTERFERON; PENCICLOVIR; PODOPHYLLOTOXIN; PROBENECID; RESIQUIMOD; RETINOID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SALICYLIC ACID; THIAZOLE DERIVATIVE; TRICHLOROACETIC ACID; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VIRUS GLYCOPROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BURNING SENSATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONDYLOMA; CRYOTHERAPY; CRYSTALLINE NEPHROPATHY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; EDEMA; ELECTROSURGERY; EPSTEIN BARR VIRUS; EROSION; ERYTHEMA; EYE INJURY; EYE TOXICITY; FATIGUE; GENITAL HERPES; GENITAL ULCER; HALLUCINATION; HEADACHE; HEMATOLOGIC DISEASE; HERPES LABIALIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNOMODULATION; INFLAMMATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; IRIDOCYCLITIS; IRITIS; IRRITABILITY; KIDNEY DYSFUNCTION; LASER SURGERY; MALAISE; METABOLIC DISORDER; MOLLUSCUM CONTAGIOSUM; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PATHOGENESIS; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RETINITIS; REVIEW; SEIZURE; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKIN INFECTION; SKIN SURGERY; TREMOR; TUBULAR DYSFUNCTION; VIRUS INFECTION; VIRUS PARTICLE; VIRUS RESISTANCE; VIRUS TRANSMISSION; VITREOUS DISEASE; VITRITIS; VOMITING; WART VIRUS;

EID: 17044417676     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2004.09.001     Document Type: Review

References (64)

1. K.A. Yeung-Yue, M.H. Brentjens, P.C. Lee, and S.K. Tyring Herpes simplex viruses 1 and 2 Dermatol Clin 20 2002 249 266
2. T.J. Brown, A. Yen-Moore, and S.K. Tyring An overview of sexually transmitted diseases, part I J Am Acad Dermatol 41 1999 511 529
3. J.G. Donohue, P.W. Choo, J.E. Manson, and R. Platt The incidence of herpes zoster Arch Intern Med 155 1995 1605 1609
4. G. Henle, W. Henle, and P. Clifford Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups J Natl Cancer Inst 43 1969 1147 1157
5. L.J. Zhang, P. Hanff, C. Rutherford, W.H. Churchill, and C.S. Crumpacker Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood J Infect Dis 171 1995 1002 1006
6. H. Masur, S.M. Whitcup, and C. Cartwright Advances in the management of AIDS-related cytomegalovirus retinitis Ann Intern Med 125 1996 126 136
7. S.L. Spruance, J.C. Stewart, N.H. Rowe, M.B. McKeough, G. Wenerstrom, and D.J. Freeman Treatment of recurrent herpes simplex labialis with oral acyclovir J Infect Dis 161 1990 185 190
8. T.Y. Evans, and S.K. Tyring Advances in antiviral therapy in dermatology Dermatol Clin 16 1998 409 419
9. J.J. Wu, M.H. Brentjens, G. Torres, K. Yeung-Yue, P. Lee, and S.K. Tyring Valacyclovir in the treatment of herpes simplex, herpes zoster, and other viral infections J Cutan Med Surg 7 2003 372 381
10. L. Corey, A. Wald, and R. Patel Once-daily valacyclovir to reduce the risk of transmission of genital herpes N Engl J Med 350 2004 11 20
11. K.R. Beutner, D.J. Friedman, C. Forszpaniak, P.L. Andersen, and M.J. Wood Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults Antimicrob Agents Chemother 39 1995 1546 1553
12. S.K. Tyring, K.R. Beutner, B.A. Tucker, W.C. Anderson, and R.J. Crooks Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older Arch Fam Med 9 2000 863 869
13. B. Romanowski, F.Y. Aoki, A.Y. Martel, E.A. Lavender, J.E. Parsons, and R.L. Saltzman Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group AIDS 14 2000 1211 1217
14. S. Tyring, R. Engst, and C. Corriveau Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study Br J Ophthalmol 85 2001 576 581
15. S. Tyring, R. Belanger, W. Bezwoda, P. Ljungman, R. Boon, and R.L. Saltzman A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients Cancer Invest 19 2001 13 22
16. S.L. Spruance, T.L. Rea, C. Thoming, R. Tucker, R. Saltzman, and R. Boon Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group JAMA 277 1997 1374 1379
17. Valganciclovir: new preparation. CMV retinitis: a simpler, oral treatment Prescribe Int 12 2003 133 135
18. J.R. Toro, S. Sanchez, G. Turiansky, and A. Blauvelt Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox Dermatol Clin 21 2003 301 309
19. R. Snoeck, G. Andrei, and M. Gerard Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) Clin Infect Dis 18 1994 570 578
20. F. Lateef, P.C. Don, M. Kaufmann, S.M. White, and J.M. Weinberg Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS Arch Dermatol 134 1998 1169 1170
21. J. Lalezari, T. Schacker, and J. Feinberg A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS J Infect Dis 176 1997 892 898
22. Vitravene Study Group Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS Am J Ophthalmol 133 2002 484 498
23. D.T. Jayaweera Minimising the dosage-limiting toxicities of foscarnet induction therapy Drug Saf 16 1997 258 266
24. M.A. Jacobson, J.G. Gambertoglio, F.T. Aweeka, D.M. Causey, and A.A. Portale Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism J Clin Endocrinol Metab 72 1991 1130 1135
25. J.J. Crute, C.A. Grygon, and K.D. Hargrave Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease Nat Med 8 2002 386 391
26. G. Kleymann, R. Fischer, and U.A. Betz New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease Nat Med 8 2002 392 398
27. P. Savio de Araujo Souza, and L. Lina Villa Genetic susceptibility to infection with human papillomavirus and development of cervical cancer in women in Brazil Mutat Res 544 2003 375 383
28. N. Munoz Human papillomavirus and cancer: the epidemiological evidence J Clin Virol 19 2000 1 5
29. Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines 2002 MMWR Morb Mortal Wkly Rep 51 2002 1 78
30. P.T. Ting, and M.T. Dytoc Therapy of external anogenital warts and molluscum contagiosum: a literature review Dermatol Ther 17 2004 68 101
31. D. Carrasco, M. vander Straten, and S.K. Tyring Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions J Am Acad Dermatol 47 Suppl 2002 S212 S216
32. T.W. Schacker, M. Conant, C. Thoming, T. Stanczak, Z. Wang, and M. Smith Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study Antimicrob Agents Chemother 46 2002 3243 3248
33. K.R. Beutner, S.K. Tyring, and K.F. Trofatter Jr Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts Antimicrob Agents Chemother 42 1998 789 794
34. K.R. Beutner, S.L. Spruance, A.J. Hougham, T.L. Fox, M.L. Owens, and J.M. Douglas Jr Treatment of genital warts with an immune-response modifier (imiquimod) J Am Acad Dermatol 38 1998 230 239
35. T.A. Syed, O.A. Ahmadpour, S.A. Ahmad, and S.H. Ahmad Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study J Dermatol 25 1998 429 433
36. K.H. Fife, A. Ferenczy, J.M. Douglas Jr, D.R. Brown, M. Smith, and M.L. Owens Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day Sex Transm Dis 28 2001 226 231
37. S. Spruance, S. Tyring, M. Smith, and T.C. Meng Application of a topically applied immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study J Infect Dis 84 2001 196 200
38. R. Snoeck, M. Bossens, and D. Parent Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection Clin Infect Dis 33 2001 597 602
39. A. Matteelli, A. Beltrame, and S. Graifemberghi Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons Sex Transm Dis 28 2001 343 346
40. S. Margolis Genital warts and molluscum contagiosum Urol Clin North Am 11 1984 163 170
41. S.T. Brown, J.F. Nalley, and S.J. Kraus Molluscum contagiosum Sex Transm Dis 8 1981 227 234
42. K.P. Meadows, S.K. Tyring, A.T. Pavia, and T.M. Rallis Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir Arch Dermatol 133 1997 987 990
43. E.G. Davies, A. Thrasher, K. Lacey, and J. Harper Topical cidofovir for severe molluscum contagiosum Lancet 353 1999 2042
44. J.R. Toro, L. Wood, and M. Turner Topical cidofovir: a novel treatment for recalcitrant molluseum contagiosum in HIV infected children Arch Dermatol 136 2000 983 985
45. D. Calista Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study J Eur Acad Dermatol Venereol 14 2000 484 488
46. A.M. Cattelan, L. Sasset, L. Corti, S. Stiffan, F. Meneghetti, and P. Cadrobbi A complete remission of recalcitrant molluscum contagiosum in an AIDS patient following highly active antiretroviral therapy (HAART) J Infect 38 1999 58 60
47. D. Calista, A. Boschini, and G. Landi Resolution of disseminated molluscum contagiosum with highly active anti-retroviral therapy (HAART) in patients with AIDS Eur J Dermatol 9 1999 211 213
48. D. Calista, M. Morri, A. Stagno, and A. Boschini Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor Am J Clin Dermatol 3 2002 59 62
49. J.J. Wu, D.B. Huang, K.R. Pang, and S.K. Tyring Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations J Am Acad Dermatol 50 2004 495 528
50. L. Corey, A.G. Langenberg, and R. Ashley Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials JAMA 282 1999 331 340
51. L.R. Stanberry, S.L. Spruance, A.L. Cunningham GlaxoSmithKline Herpes Vaccine Efficacy Study Group Glycoprotein-D-adjuvant vaccine to prevent genital herpes N Engl J Med 347 2002 1652 1661
52. M.E. Boursnell, C. Entwisle, and D. Blakely A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease J Infect Dis 175 1997 16 25
53. C.S. McLean, D.N. Challanin, I. Duncan, M.E. Boursnell, R. Jennings, and S.C. Inglis Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine Vaccine 14 1996 987 992
54. G. Casanova, R. Cancela, and L. Alonzo A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections Cutis 70 2002 235 239
55. Reichman R., Balsley J., Carlin D., et al. Evaluation of the safety and immunogenicity of a recombinant HPV-11 L1 virus like particle vaccine in healthy adult volunteers. In: Gurley M., Carter C.D., Bounassif S., et al., editors. Proceedings of the 17th International Papillomavirus Conference. Charleston, SC, January 9-15, 1999
56. Zhang L.F., Zhou J., Shao C., et al. A phase 1 trial of HPV 6 B virus like particles as immunotherapy for genital warts. International Papillomavirus Conference. Charleston, SC, January 9-15, 1999
57. D.D. Silva, J. Nieland, H. Greenstone, J. Schiller, and W. Kast Chimeric papillomavirus virus-like particles induce antigen-specific therapeutic immunity against tumours expressing the HPV-16 E7 protein International Papillomavirus Conference 17th edition 1999
58. L.A. Koutsky, K.A. Ault, and C.M. Wheeler A controlled trial of a human papillomavirus type 16 vaccine N Engl J Med 347 2002 1645 1651
59. C.J. Lacey, E.F. Monteiro, and H.S. Thompson A phase IIa study of a therapeutic vaccine for genital warts 1997 Medical Society for the Study of Venereal Disease Oxford, UK
60. The Jordan report. Accelerated development of vaccines, 2002 2002 National Institute of Allergy and Infectious Diseases Bethesda, MD
61. L.K. Borysiewicz, A. Fiander, and M. Nimako A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer Lancet 347 1996 1523 1527
62. E.R. Jensen, R. Selvakumar, H. Shen, R. Ahmed, F.O. Wettstein, and J.F. Miller Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA J Virol 71 1997 8467 8474
63. M.A. Ossevoort, M.C. Feltkamp, K.J. van Veen, C.J. Melief, and W.M. Kast Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor J Immunother Emphasis Tumor Immunol 18 1995 86 94
64. M.F. Duggan-Keen, M.D. Brown, S.N. Stacey, and P.L. Stern Papillomavirus vaccines Front Biosci 3 1998 1192 1208